Michael Hearne - Jan 14, 2022 Form 4 Insider Report for LA JOLLA PHARMACEUTICAL CO (LJPC)

Role: Chief Financial Officer
Signature: /s/ Michael Hearne
Stock symbol: LJPC
Transactions as of: Jan 14, 2022
Transactions value $: $619
Form type: 4
Date filed: 1/19/2022, 07:26 PM
Previous filing: Jan 14, 2022
Next filing: Feb 2, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LJPC	Common Stock	Award	$619	+148	+2.3%	$4.18	6.58K	Jan 14, 2022	Direct	F1
holding	LJPC	Common Stock						9.61M	Jan 14, 2022	By LP	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LJPC	Employee Stock Option (Right to Buy)	Award	$0	+148		$0.00	148	Jan 14, 2022	Common Stock	148	$4.92	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired on 1/14/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2	The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP.
F3	The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years.